Slide 1: Increased sales, gradually strengthened margins and stable cash flows
Increased sales, gradually strengthened margins and stable cash flows Getinge Q3 2023 Mattias Perjos, CEO Lars Sandström, CFO
Slide 2: Key takeaways
Key takeaways Q3 2023 • Net sales increased by 5.7% and order intake decreased by 1.9% organically • Improvements in Cardiac Assist and Cardiopulmonary • Margins strengthened sequentially in the quarter • Completed acquisitions of Healthmark and High Purity New England (after the end of the quarter)
Slide 3: Key activities and events
Key activities and events Q3 2023 Sustainability and Quality Offering and customers • Emissions, energy consumption and renewables • Clearance from the US FDA for Servo-air® Lite continue to develop in a positive direction ventilator • SBTi validated* Getinge’s near and long-term • Launched AppliFle
Slide 4: Healthmark – a perfect fit
Healthmark – a perfect fit A solid contribution to Surgical Workflows • Strong brand with unwavering commitment to create customer value including education and training • Broadens Surgical Workflows’ consumables portfolio – minimal overlap • Strengthens the US platform with enhanced customer access
Slide 5: Cardiopulmonary – addressing packaging challenges
Cardiopulmonary – addressing packaging challenges Extension for HLS/PLS until September 2024 Hardware, service & other consumables HLS/PLS > 4 BSEK Cardiopulmonary sales 2022 Quadrox Quadrox HLS/PLS ‒ Consumables (Surgical Perfusion and ECMO) with high gross margin ‒ Consumables (ECMO) with high gro
Slide 6: Cardiac Assist – corrected the component issue
Cardiac Assist – corrected the component issue Large deliveries of balloons, reinstated CE mark for the IAB Pump Intra-Aortic Balloon Pumps and Service Intra-Aortic < 2 BSEK Balloons Cardiac Assist sales 2022 Intra-Aortic Balloons Intra-Aortic Balloon Pumps ‒ High gross margin ‒ Medium gross margin
Slide 7: Solid net sales growth in all regions
Solid net sales growth in all regions Acute Care Therapies is the main reason behind the soft order intake Global Americas EMEA APAC -1.9% Organic Order Growth +5.7% Organic Net Sales Growth Getinge │ Presentation │ Q3 Report 2023 October 23, 2023
Slide 8: Outlook 2023
Outlook 2023 Net sales for 2023 are expected to increase by 2-5% organically Getinge │ Presentation │ Q3 Report 2023 October 23, 2023
Slide 9: Weak order intake in Acute Care Therapies in the quarter
Weak order intake in Acute Care Therapies in the quarter Order Intake Bridge Q3 2022 – Q3 2023 Organic change -7.6% +8.5% +3.6% -1.9% +1.7% 200 142 7,712 MSEK -214 7,584 Q3 2022 Acute Care Therapies Life Science Surgical Workflows Q3 2023 Getinge │ Presentation │ Q3 Report 2023 October 23, 2023
Slide 10: Strong net sales in Acute Care Therapies and Surgical Workflows
Strong net sales in Acute Care Therapies and Surgical Workflows Net Sales Bridge Q3 2022 – Q3 2023 Organic change +6.0% 0.0% 7.4% 5.7% +9.6% 261 +271 Currency impact, MSEK 355 52 6.9 7,607 MSEK Organic growth, % 3.5 6,941 Q3 2022 Acute Care Life Science Surgical Q3 2023 Capital Recurring Therapies W
Slide 11: Adj Gross Margin negatively impacted by mix effects, inflation and FX
Adj Gross Margin negatively impacted by mix effects, inflation and FX Adjusted Gross Profit Bridge Q3 2022 – Q3 2023 Adj GM, % Q3 2023 60.4 35.6 41.3 51.1 (Q3 2022) (61.0) (40.1) (40.4) (51.8) Gross Margin impact +8.3% 193 127 Product and Geo mix -22 Supply, Absorption & Cost inflation MSEK 3,890 3,
Slide 12: Adj EBITA margin impacted by higher OPEX
Adj EBITA margin impacted by higher OPEX Adjusted EBITA Bridge Q3 2022 – Q3 2023 16.9% 14.5% Margin development -0.3 pp Adj GP -5.9% -2.3 pp Adj OPEX 298 -0.3 pp FX +0.5 pp D&A -79 -171 -23 -77 -15 +17 Currency impact, MSEK MSEK 1,170 1,101 Q3 2022 Adj Gross Adj Selling Adj Admin Adj R&D Other D&A Q
Slide 13: Stable Free Cash Flow and Working Capital days below 100
Stable Free Cash Flow and Working Capital days below 100 Capital efficiency a priority Healthy Free Cash Flow WC days below 100 ROIC below trend, but still well above pre pandemic levels 200 1.1 1.0 150 0.7 0.3 100 11.3% 7.5% -0.7 0 Q3 2023 Q2 2018 Q2 2019 Q2 2020 Q2 2019 Q2 2020 Q3 2022 Q4 2022 Q1
Slide 14: Solid financial position
Solid financial position Margin of safety when it comes to net debt and leverage Net debt is down significantly in recent years … … and leverage is signalling financial strength 14.0 Leverage after acquisitions of Net debt after acquisitions of Healthmark 3.4x Healthmark and HPNE (pro-forma net and
Slide 15: Summary
Summary Getinge │ Presentation │ Q3 Report 2023 October 23, 2023
Slide 16: Key takeaways
Key takeaways Summary Q3 2023 • Healthy net sales growth • Improvements in Cardiac Assist and Cardiopulmonary • Gradually improved margins • Strengthened our offering through launches and acquisitions • Solid Free Cash Flow and financial position Getinge │ Presentation │ Q3 Report 2023 October 23, 2
Slide 17: Q&A
Q&A Getinge │ Presentation │ Q3 Report 2023 October 23, 2023
Slide 18: Thank you
Thank you Getinge │ Presentation │ Q3 Report 2023 October 23, 2023
Slide 19: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 20: Getinge – Passion for Life
“= Se A GETINGE PASSION FOR LIFE